Illumina Debuts BioInsight Platform, Expands AI Tools for Genomic Research

MT Newswires Live10-14 21:54

Illumina (ILMN) launched its BioInsight Platform, combining genomic analysis tools, AI models and biological datasets to simplify genomic and multiomic research, the company said Wednesday.

The platform includes DRAGEN v4.6, which expands deployment options across supported cloud and CPU environments while maintaining consistent analysis results, the company said.

The platform integrates applications such as Emedgene, Connected Multiomics and BaseSpace, curated biological datasets, and usage-based BioInsight Credits that replace annual subscriptions, the company added.

Illumina shares were up 2% in Wednesday trading.

Price: 275.04, Change: +3.87, Percent Change: +1.43

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment